Table 1

%Patient characteristics and results of p16INK4 methylation and p53 mutation

PtHistologyAgeSexMeta siteCTEffectp16 Methyla Primp16 Methyl Metap53 mut Primp53 mut Meta
1adeno57MLiver+MRunun
2adeno40FLung+NENDND
3adeno49MLiver+PDunun
4adeno60FLiver+PRunun
5adeno61MLiver+NENDND
6adeno74MMuscleunun++
7adeno65FLung+NCunMethyl
8adeno63MPleura+NCMethylMethyl
9adeno52MPleura+NEunun
10adeno47MPancreas+NEunun++
11adeno74FLung+NCunun
12adeno60MLiverunun++
13adeno74FLung+PRunMethyl
14ad-sq64MLiverunMethyl
15sq70MLung+PDunun++
16sq69MLung+NCunMethyl
17sq58MLung+PRMethylMethyl++
18sq82FLiverNCunun++
19sq74MLung+NCunMethyl
20sq71MLiver+NCunMethyl
21sq80MBronchus+MRunun
22sq64MLung+PDunMethyl
23sq57FSubcuta+NCunun
24small77MLung+NEunun++
25small80MLiver+PRunun++
26small48MSpleen+PDunun++
27small62MLiver+PRunMethyl
28small53MLiver+PRunun
29small48FLiver+PRunun
  • a Methyl, methylated; un, unmethylated; adeno, adenocarcinoma; sq, squamous cell carcinoma; ad-sq, adeno-squamous cell carcinoma; CT, chemotherapy; Effect, response to chemotherapy; Prim, Primary; Meta, Metastasis; mut, mutation; PR, partial response; MR, minor response; NC, no change; PD, progressive disease; NE, not evaluated; ND, not done.